Neil Abdollahian
Corporate Officer/Principal chez BOUNDLESS BIO, INC.
Fortune : - $ au 31/03/2024
Profil
Neil Abdollahian is currently the Chief Business Officer at Boundless Bio, Inc. He previously held positions as the Assistant Director at Ionis Pharmaceuticals, Inc. from 2004 to 2005, Director-Business Development at Avanir Pharmaceuticals, Inc. from 2005 to 2007, Director-Business Development & Special Projects at Emerging Growth Capital Ltd., Managing Director at Clarity Point Partners LLC, Manager-Business Development at Neurogen Corp.
from 2001 to 2004, and Vice President-Corporate Development at Trius Therapeutics, Inc. from 2011 to 2013.
He also served as the Chief Business Officer at Cidara Therapeutics, Inc. from 2016 to 2021.
Mr. Abdollahian obtained his undergraduate degree from George Washington University in 1995, an MBA from Pepperdine University, and a graduate degree from the University of New Mexico School of Medicine in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BOUNDLESS BIO INC.
-.--% | 27/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Neil Abdollahian
| Sociétés | Poste | Début |
|---|---|---|
| BOUNDLESS BIO, INC. | Corporate Officer/Principal | 01/08/2021 |
Anciens postes connus de Neil Abdollahian
| Sociétés | Poste | Fin |
|---|---|---|
| CIDARA THERAPEUTICS, INC. | Corporate Officer/Principal | 02/08/2021 |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/12/2013 |
| AVANIR PHARMACEUTICALS INC | Corporate Officer/Principal | 01/01/2007 |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2005 |
Neurogen Corp.
 Neurogen Corp. Pharmaceuticals: MajorHealth Technology Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT. | Corporate Officer/Principal | 01/01/2004 |
Formation de Neil Abdollahian
| George Washington University | Undergraduate Degree |
| Pepperdine University | Masters Business Admin |
| University of New Mexico School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| CIDARA THERAPEUTICS, INC. | Health Technology |
| BOUNDLESS BIO, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Neurogen Corp.
Neurogen Corp. Pharmaceuticals: MajorHealth Technology Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT. | Health Technology |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
| Emerging Growth Capital Ltd. | Finance |
| Clarity Point Partners LLC |
